Company intelligence / Profile preview

Nalagenetics

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Nalagenetics provides genetic testing services with a focus on Southeast Asian populations. Their initial study found that 20% of leprosy patients in Papua carried genes predisposing them to severe reactions to Dapsone, allowing for personalized treatment plans.

Therapeutic areas: OtherMetabolic Disorders
Modalities: Genetic testingDNA analysis
Industry: Molecular Diagnostics

Partnerships

Indonesian health ministryhospitals and research facilities in Jakarta and Singapore

Beyond the preview

Go deeper on Nalagenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nalagenetics.

Explore the full profile